EODData

NASDAQ, BEAM: Beam Therapeutics Inc

26 Nov 25 15:59
LAST:

25.03

CHANGE:
 0.34
OPEN:
26.00
HIGH:
26.00
ASK:
0.00
VOLUME:
821.2K
CHG(%):
1.38
PREV:
24.69
LOW:
24.38
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Nov 2526.0026.0024.3825.03821.2K
25 Nov 2523.4925.2523.3324.693.63M
24 Nov 2522.4523.8822.3023.642.8M
21 Nov 2520.5122.4820.3922.211.95M
20 Nov 2521.4022.2720.2320.601.62M
19 Nov 2522.0022.4720.9620.981.65M
18 Nov 2521.7622.5621.2621.921.6M
17 Nov 2521.1522.7220.8022.022.03M
14 Nov 2520.9822.1420.7621.722.2M
13 Nov 2521.6124.0821.1621.663.65M

PROFILE

Name:Beam Therapeutics Inc
About:Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:238 Main Street, Cambridge, MA, United States, 02142
Website:https://beamtx.com
CUSIP:07373V105
CIK:0001745999
ISIN:US07373V1052
FIGI:BBG00KXC8646

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:-5.29 
Forward P/E:-5.24 
PEG Ratio:0.53 
Price to Sales:41.98 
Price to Book:2.34 
Operating Margin:-14.19 
Return on Assets:-0.21 
Return on Equity:-0.42 
EPS Ratio:-4.50 
Revenue:60.27M 
Shares:101.16M 
Market Cap:2.532B 

TECHNICAL INDICATORS

MA5:23.237.7%
MA10:22.4511.5%
MA20:22.7410.1%
MA50:24.601.8%
MA100:21.9114.3%
MA200:21.0918.7%
STO9:82.04 
STO14:82.04 
RSI14:60.04 
MTM14:2.82
ROC14:0.13 
ATR:1.78 
Week High:26.003.9%
Week Low:20.2323.7%
Month High:27.5710.1%
Month Low:20.2318.7%
Year High:35.2540.8%
Year Low:13.5385.1%
Volatility:78.86